CNR1 and schizophrenia: Our results may also have future implications for the pharmacological treatment of SUDs, as they suggest that CB1 or PPARs agonists would be required in substance abusers, whereas CB1 or PPAR antagonists would be required in dual-diagnosis schizophrenia patients.